Amyl Nitrite Inhalant

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Amyl nitrite 98%{relative}

Disponibbli minn:

Baxter Healthcare Ltd

INN (Isem Internazzjonali):

Amyl nitrite 98% w/v

Dożaġġ:

98% w/v

Għamla farmaċewtika:

Volatile liquid for inhalation

Kompożizzjoni:

Active: Amyl nitrite 98%{relative} Excipient: Epoxidised linseed oil

Unitajiet fil-pakkett:

Ampoule, glass, crushable, in boxes of 12, 3.6 mL

Klassi:

Prescription

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

James Alexander Corporation

Sommarju tal-prodott:

Package - Contents - Shelf Life: Ampoule, glass, crushable, in boxes of 12 - 3.6 mL - 24 months from date of manufacture stored at 8° to 15°C (Cool) 36 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Data ta 'l-awtorizzazzjoni:

1992-08-19

Karatteristiċi tal-prodott

DATA SHEET 
AMYL NITRITE 
_INHALANT _
PRESENTATION 
Amyl nitrite is
a rapidly acting vasodilator administered by inhalation. 0.3mL is
supplied 
in a covered thin glass capsule which is easily
crushed between the fingers. Amyl nitrite 
is a clear, yellowish liquid having a peculiar
ethereal, fruity odour. It is volatile, even at 
low temperatures, and is
flammable. This product is 98% w/v, stabilized with Epoxol 9-
5, 2%w/v. The structural formula of amyl nitrite is (CH
3
)
2
CHCH
2
CH
2
ONO. 
USES 
_ACTIONS _
Amyl nitrite causes a non-specific
relaxation of smooth muscle with the most prominant 
actions occurring in vascular
smooth muscle. This effect on vascular smooth muscle 
results in coronary vasodilation and decreased systemic vascular
resistance and left 
ventricular preload and afterload. Additionally, amyl
nitrite induces the formation of 
methemoglobin. In cases
of cyanide poisoning, the methemoglobin combines with the 
cyanide to form nontoxic cyanmethemoglobin. 
_PHARMACOKINETICS _
Amyl nitrite vapours
are absorbed rapidly through the pulmonary alveoli, manifesting 
therapeutic effects within one minute after
inhalation. The drug is metabolised rapidly, 
probably by hydrolytic denitration; approximately one third of the inhaled amyl
nitrite is 
excreted in the urine. 
INDICATIONS 
Amyl nitrite is indicated for
the treatment of cyanide poisoning in the conscious patient. 
DOSAGE AND ADMINISTRATION 
With the patient in a recumbent or
seated position a capsule of amyl nitrite is crushed 
between the fingers and held under
the patient's nose. Inhalations should be 
administered for up to 30 seconds every 2 minutes, using a fresh capsule each time 
until signs of recovery occur. Up to 8 capsules
may be given if there is a delay in 
administering intravenous antidotes. 
Safety and effectiveness
in